Exchange: NASDAQ·Updated 07:50 PM EDT
PRME logo

PRMEPrime Medicine Inc

$3.23
$0.07
(2.21%)
Today
Closed $3.23
$0.03
(0.93%)
After Hours
EarningsAug 6
Mkt Cap$583.39M
Vol3.5M
32

Bearish Sentiment

How do you feel about PRME?

News
all
press releases
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsOcular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -15.99% and -45.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
RenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
RenovoRx (RNXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -27.94% and -3.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen
Wall Street Zen raised shares of Prime Medicine from a "strong sell" rating to a "sell" rating in a research note on Tuesday...
MarketBeat
News Placeholder
Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Prime Medicine from a "sell" rating to a "strong sell" rating in a research report on Monday...
MarketBeat
News Placeholder
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by Brokerages
Prime Medicine, Inc. (NASDAQ:PRME - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports. One analyst...
MarketBeat
News Placeholder
Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell
Wall Street Zen upgraded Prime Medicine from a "strong sell" rating to a "sell" rating in a research note on Sunday...
MarketBeat
News Placeholder
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME
Sumitomo Mitsui Trust Group Inc. lowered its holdings in Prime Medicine, Inc. (NASDAQ:PRME - Free Report) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat
News Placeholder
Prime Medicine Appoints Svetlana Makhni As Chief Financial Officer
(RTTNews) - Prime Medicine, Inc. (PRME), a developer of a new class of differentiated one-time curative genetic therapies, said on Thursday that it has appointed Svetlana Makhni as Chief Financial...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.